Bradykinin antagonists: new opportunities

The pro-inflammatory, pain producing, and cardiovascular effects of bradykinin B 2 receptor activation are well characterized. Bradykinin B 1 receptors also produce inflammation and pain. Therefore, antagonists are expected to be anti-inflammatory/analgesic drugs. Other exploitable clinical opportun...

Full description

Saved in:
Bibliographic Details
Published inCurrent Opinion in Chemical Biology Vol. 4; no. 4; pp. 401 - 406
Main Authors Bock, Mark G, Longmore, Jeanette
Format Book Review Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.08.2000
Subjects
B1 receptor
B2 receptor
Bradykinin - antagonists & inhibitors
Bradykinin antagonists
bradykinin B1 receptors
Bradykinin Receptor Antagonists
Cyclo-oxygenase
Drug Stability
Forecasting
Humans
Molecular Structure
Oligopeptides - chemistry
Oligopeptides - pharmacology
Chemical biology
Bradykinin antagonists
B2 receptor
Cyclo-oxygenase
Pharmacology
Drug discovery
B1 receptor
Molecular medicine
Online AccessGet full text

Cover

More Information
Summary:The pro-inflammatory, pain producing, and cardiovascular effects of bradykinin B 2 receptor activation are well characterized. Bradykinin B 1 receptors also produce inflammation and pain. Therefore, antagonists are expected to be anti-inflammatory/analgesic drugs. Other exploitable clinical opportunities may exist. The newly discovered non-peptide B 2 receptor antagonists and the equivalent B 1 receptor pharmacological agents, which are in the pipeline, are suitable preclinical tools to properly evaluate potential utilities.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:1367-5931
1879-0402
DOI:10.1016/S1367-5931(00)00107-1